The FDA Approval That Skipped the Biggest Test in Drug Development

Vanda had spent seven years fighting for that jet lag indication. Seven. They filed their first application in 2019 and got rejected. They appealed. The FDA went silent. Vanda literally sued the agency in 2022 to force a response. A court sided with Vanda in 2025, calling the FDA's earlier refusal "cursory" and ordering a re-review. The FDA re-reviewed it, and in January 2026... rejected it again.

The reason? The FDA argued that Vanda's clinical trials used controlled bedtime shifts to simulate jet lag, but those lab conditions didn't account for real-world travel factors like cabin pressure, noise, and crappy airplane lighting. Vanda had compelling data on sleep improvement, but the FDA wanted proof from actual transatlantic flights, not simulated ones.

Vanda's shares dropped 11% on that rejection. It was a gut punch after years of legal battles and regulatory limbo.

But then came December 2025, when the FDA approved Nereus (tradipitant) for motion sickness, Vanda's first new drug approval in years. And barely two months later, Bysanti crossed the finish line. Two new FDA approvals in under 60 days, after nearly a decade of banging their heads against the wall on Hetlioz.

That's one hell of a comeback arc.

What Wall Street Thinks

Analysts didn't waste time upgrading their outlook. HC Wainwright raised its price target to $24 with a Buy rating. B. Riley Financial bumped its target to $14, calling Vanda an "ongoing turnaround story." Cantor Fitzgerald maintained an Overweight rating, and even Jefferies, the most cautious of the bunch with a Hold rating, raised its target to $7.50 from $5.

Three of four covering analysts now rate Vanda a Buy. The average price target of $13.63 implies 137% upside from the stock's recent close. For a company trading under $9, that's a bold call.

The bull case isn't just about Bysanti, though. Vanda is eyeing the broader antipsychotic market, which the company pegs at roughly $18-20 billion globally. And Bysanti's unique receptor binding profile (it hits alpha-adrenergic receptors harder than dopamine or serotonin receptors) could open doors in conditions involving agitation and hyperarousal that other antipsychotics don't address as well.

The Bigger Lesson Hiding in This Approval

Vanda's story is really a tale of two regulatory strategies, and the contrast is stark.

On one hand, you have Hetlioz and jet lag: a novel indication expansion for an existing drug. Vanda had to prove that a medication already approved for a rare sleep disorder could work for something entirely different. The FDA held them to a brutal standard, demanding real-world evidence that their controlled trials couldn't provide. Seven years, multiple lawsuits, two rejections.

On the other hand, you have Bysanti: a formulation play where the active compound is functionally identical to an approved drug. Show bioequivalence, point to the existing safety database, and you're in. No Phase 3. Approved in a fraction of the time.

The lesson? In CNS drug development, reformulating a known molecule faces a dramatically lower regulatory bar than expanding an approved drug into a new indication. That might sound obvious in hindsight, but it has real implications for how biotech companies allocate R&D dollars. Sometimes the smartest move isn't discovering something new; it's repackaging something proven.

What's Next

Bysanti is expected to hit the market in Q3 2026. But Vanda isn't done. The company is running a Phase 3 trial testing Bysanti as a once-daily add-on treatment for people with major depression who haven't responded to other therapies. Results are expected by the end of 2026.

There's also a long-acting injectable version of iloperidone (Fanapt) in Phase 3 development, which could give Vanda a monthly shot option in a market that increasingly values convenience and adherence.

And then there's Imsidolimab, Vanda's drug for generalized pustular psoriasis, which could see an FDA decision as early as mid-2026 under priority review.

After years of being the company that couldn't catch a break on jet lag, Vanda suddenly has a pipeline that looks like it was built by someone who learned from every setback. The Hetlioz saga was expensive and frustrating, but the Bysanti approval proves something important: sometimes the best path forward isn't through a wall. It's around it.

Moderna Just Sold a Rare Disease Drug for Pennies on the Dollar

Moderna handed Recordati the commercial rights to a potentially first-in-class rare disease therapy for just $50 million upfront. Leerink analysts called it a "garage sale," and the math backs them up.